These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38347114)

  • 1. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
    Nixon AB; Liu Y; Yang Q; Luo B; Starr MD; Brady JC; Kelly WK; Beltran H; Morris MJ; George DJ; Armstrong AJ; Halabi S
    Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38347114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
    Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
    Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
    Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
    Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
    Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
    Kelly WK; Halabi S; Carducci M; George D; Mahoney JF; Stadler WM; Morris M; Kantoff P; Monk JP; Kaplan E; Vogelzang NJ; Small EJ
    J Clin Oncol; 2012 May; 30(13):1534-40. PubMed ID: 22454414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
    Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
    Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
    Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
    BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
    Liu Y; Lyu J; Bell Burdett K; Sibley AB; Hatch AJ; Starr MD; Brady JC; Hammond K; Marmorino F; Rossini D; Goldberg RM; Falcone A; Cremolini C; Owzar K; Ivanova A; Moore DT; Lee MS; Sanoff HK; Innocenti F; Nixon AB
    Mol Cancer Ther; 2020 Oct; 19(10):2146-2154. PubMed ID: 32747417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
    Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
    Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
    Rimassa L; Kelley RK; Meyer T; Ryoo BY; Merle P; Park JW; Blanc JF; Lim HY; Tran A; Chan YW; McAdam P; Wang E; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
    Liver Cancer; 2022 Jan; 11(1):38-47. PubMed ID: 35222506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
    Nixon AB; Pang H; Starr MD; Friedman PN; Bertagnolli MM; Kindler HL; Goldberg RM; Venook AP; Hurwitz HI;
    Clin Cancer Res; 2013 Dec; 19(24):6957-66. PubMed ID: 24097873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).
    Nixon AB; Halabi S; Liu Y; Starr MD; Brady JC; Shterev I; Luo B; Hurwitz HI; Febbo PG; Rini BI; Beltran H; Small EJ; Morris MJ; George DJ
    Clin Cancer Res; 2022 Jul; 28(13):2771-2778. PubMed ID: 34965953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
    Ryan CJ; Dutta S; Kelly WK; Russell C; Small EJ; Morris MJ; Taplin ME; Halabi S;
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):66-73. PubMed ID: 31053766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
    Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
    Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
    Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
    BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.